Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris
18 December 2019
OHE presented at the Global AMR R&D Hub Board of Members Meeting in Paris, on adapting HTA and payment mechanisms to incentivise new drugs to tackle…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
A new OHE Research Paper summarises the findings of a project funded by the Wellcome Trust on innovative HTA methods and contracting for antibiotics. The paper…
OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?
19 August 2019
OHE Lunchtime Seminar with Steve McKenna, 17th September 2019. The seminar will examine conceptual and practical aspects of measuring value in health care.
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden.…
OHE Lunchtime Seminar: Health Years in Total (HYT): A New Health Objective Function for Cost-effectiveness Analysis
20 June 2019
OHE Lunchtime Seminar with Anirban Basu, 24th July 2019. The seminar will examine conceptual and theoretic arguments for use of HYT and illustrate their performance.
OHE at the 2019 Health Technology Assessment International (HTAi) Annual Meeting
7 June 2019
Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June.
Can We Really Compare and Aggregate Patient-reported Outcomes Between People and Settings?
11 April 2019
A new OHE Research Paper considers whether we can compare and aggregate patient-reported outcome (PRO) data between people and settings. The paper is authored by Nancy…
Quality of Life and Rare Disease: Lessons from Spinal Muscular Atrophy
2 April 2019
The measurement of quality of life in the context of spinal muscular atrophy (SMA) is challenging. This is because the disease is experienced by children and…
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
20 March 2019
Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. A new OHE report provides empirical…